Appointment

RNS Number:9564Z
Ardana PLC
17 March 2006

               Ardana appoints Klaus Falk as VP Sales & Marketing


Edinburgh, UK, 17 March 2006;  Ardana plc (LSE:ARA) the emerging pharmaceutical
company focused on improving human reproductive health, announces the
appointment of Klaus Falk as Vice President, Sales & Marketing.

Mr Falk, aged 46, has over 20 years of experience in the pharmaceutical
industry, gained at Merck KGaA in a number of posts including 8 years as a
General Manager in Central and South America. Whilst based in Germany, he gained
experience in a range of strategic projects including M&A and the company's IPO
in 1995. As Vice President, Europe, he was responsible for Sales & Marketing and
his achievements included the successful launch of the oncology franchise's
first product, Erbitux, in 2003.

Commenting, Dr Maureen Lindsay, Ardana's CEO, said, "Klaus's deep and broad
experience over the last 20 years will bring significant benefits to Ardana as
we build further on our sales and marketing capabilities in the UK and Europe.
With Striant on the market; a planned launch for Invicorp later this year, and
various in-licensing opportunities, we are delighted that Klaus will be leading
these key activities".


For more information contact:

Ardana                                     Financial Dynamics
Maureen Lindsay                            (corporate/financial media relations)
Tel: + 44 (0) 131 226 8550                 Julia Phillips/John Gilbert
                                           Tel: [phone]

                                           NB Public Relations
                                           trade/technical media relations)
                                           Nicki Brimicombe
                                           Tel: + 44 (0)1883 732353


About Ardana

Ardana plc is a pharmaceutical company focused on the discovery, development and
marketing of innovative products to improve human reproductive health, a $23.8
billion market.

Since its foundation, Ardana has maintained a broad and balanced portfolio to
manage risk and actively pursues product and technology in-licensing and
out-licensing to maintain a robust pipeline.

Ardana's four lead products are summarised below:

  * Striant(TM) SR, a testosterone replacement therapy for which Ardana has
    marketing rights in Europe, has already been launched by Ardana through its
    own sales force in the UK as a treatment for men with confirmed hypogonadism
  * Teverelix LA, in development for three initial indications: prostate
    cancer and benign prostatic hyperplasia (both indications are at the phase
    II stage), and endometriosis (currently in phase I)
  * Testo Cream, a transdermal testosterone delivery system in phase II for
    the treatment of male hypogonadism
  * Invicorp(R), an injectable combination drug treatment for erectile
    dysfunction, already approved in Denmark and for which Ardana has marketing
    and manufacturing rights in Europe. Launch is expected in H2 2006

In addition, Ardana has a strong portfolio of follow-on products in development.
Ardana completed its IPO on the London Stock Exchange in March 2005 raising
#21 million.

For further information please see www.ardana.co.uk


                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

MSCUNUBRNVROAAR